BridgeBio Pharma, Inc.

Pharmaceutical Preparations·PALO ALTO, CA·FY end 12/31·CIK 1743881

CEO Pay Ratio

37:1

Neil Kumar

CEO Total Comp

$14.9M

Neil Kumar

Median Employee

$399,120

Revenue

$502.1M

FY 2025

Net Income

—

FY 2025

Free Cash Flow

-$447.0M

FY 2025

Net Margin

—

Insider Net (180d)

-$50.9M

0 buys / 81 sales

CEO Pay Accountability

CEO comp as % of net income

—

Not enough data to compute.

CEO comp as % of buybacks

30.96%

CEO comp equals 309.6‰ of cash returned to shareholders via buybacks.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$502.1M	$221.9M	$9.3M	$77.6M	$69.7M
Gross Profit	—	—	—	—	—	—
Operating Income	-$523.4M	-$593.0M	-$607.4M	-$512.2M	-$576.6M
Net Income	—	—	—	—	—	—
Operating CF	-$445.9M	-$520.7M	-$527.7M	-$419.5M	-$497.9M
Capex	$1.1M	$933.0K	$1.3M	$4.8M	$13.2M
Free Cash Flow	-$447.0M	-$521.7M	-$529.0M	-$424.3M	-$511.2M
Buybacks	$48.3M	—	$0	$0	$200.0M
Dividends	—	—	—	—	—	—

Gross Margin	—	—	—	—	—	—
Operating Margin	-104.2%	-267.2%	-6528.8%	-659.6%	-827.1%
Net Margin	—	—	—	—	—	—
FCF Margin	-89.0%	-235.1%	-5686.6%	-546.5%	-733.2%
R&D / Revenue	90.0%	228.2%	4898.5%	514.5%	646.9%
Effective Tax	-0.1%	-0.2%	—	—	—
Debt / Equity	-0.96	-0.30	-0.33	-0.34	-0.60
Buybacks / FCF	-10.8%	—	0.0%	0.0%	-39.1%

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Neil KumarPh.D. Chief Executive Officer	$1.0M	$10.6M	$1.9M	$1.4M	$15.3K	$14.9M
Thomas TrimarchiPh.D. President and Chief Financial Officer	$675.6K	$4.6M	—	$525.0K	$29.3K	$5.8M